Susceptibility to Tigecycline and Linezolid Among Gram-Positive Isolates Collected in the United States as Part of the Tigecycline Evaluation and Surveillance Trial (TEST) Between 2004 and 2009

Clinical Therapeutics

Volumn 33, Issue 12, 2011, Pages 1964-1973

  Dowzicky, Michael J ^a  

^a PFIZER INC   (United States)

Author keywords

Linezolid; Resistance; Surveillance; Tigecycline

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ACETAMIDES; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; OXAZOLIDINONES; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; UNITED STATES; VANCOMYCIN RESISTANCE;

EID: 83455210362     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.010     Document Type: Article

References (23)

1. Boucher H.W., Talbot G.H., Bradley J.S., et al. Bad bugs, no drugs: no ESKAPE!. An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
2. Denys G.A., Koch K.M., Dowzicky M.J. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Am J Infect Control 2007, 35:521-526.
3. Dowzicky M.J., Chmelařová E. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009. Int J Antimicrob Agents 2011, 37:562-566.
4. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard 2009, Clinical and Laboratory Standards Institute, CLSI, Wayne, Pa, CLSI document M7-A8. 8th ed.
5. Performance Standard for Antimicrobial Susceptibility Testing; 20th Informational Supplement 2010, Clinical and Laboratory Standards Institute, CLSI document M100-S20, CLSI, Wayne, Pa.
6. Performance Standard for Antimicrobial Susceptibility Testing, 20th Information Supplement (June 2010 Update) 2010, Clinical and Laboratory Standards Institute, CLSI document M100-S20U, CLSI, Wayne, Pa.
7. Tygacil [package insert] 2011, Pfizer Inc. (Wyeth Pharmaceuticals), Philadelphia, Pa.
8. Alliance for the Prudent Use of Antibiotics (APUA), Accessed September 8, 2011. http://www.tufts.edu/med/apua/index.shtml.
9. Rice L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008, 197:1079-1081.
10. Tillotson G.S., Draghi D.C., Sahm D.F., et al. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study. J Antimicrob Chemother 2008, 62:109-115.
11. Styers D., Sheehan D.J., Hogan P., et al. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006, 5:2.
12. Bordon J., Master R.N., Clark R.B., et al. Methicillin-resistant Staphylococcus aureus resistance to non-β-lactam antimicrobials in the United States from 1996 to 2008. Diagn Microbiol Infect Dis 2010, 67:395-398.
13. Kallen A.J., Mu Y., Bulens S., et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010, 304:641-648.
14. Draghi D.C., Benton B.M., Krause K.M., et al. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008, 52:2383-2388.
15. Jones M.E., Draghi D.C., Thornsberry C., et al. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004, 3:14.
16. Bradford P.A., Weaver-Sands D.T., Petersen P.J. In vitro activity of tigecycline against isolates from patients enrolled in Phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005, 41:S315-S332.
17. Huycke M.M., Sahm D.F., Gilmore M.S. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis 1998, 4:239-249.
18. Jones R.N., Fritsche T.R., Sader H.S., et al. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 2007, 59:309-317.
19. Performance Standard for Antimicrobial Susceptibility Testing, 18th InformationSupplement 2008, Clinical and Laboratory Standards Institute, CLSI document M100-S18, CLSI, Wayne, Pa.
20. Sahm D.F., Brown N.P., Thornsberry C., et al. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med 2008, 120(3 Suppl 1):16-24.
21. Bradford P.A., Petersen P.J., Tuckman M., et al. In vitro activity of tigecycline and occurrence of tetracycline resistant determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia. Clin Microbiol Infect 2008, 14:882-886.
22. Hussar D.A. New drugs of 2003. J Am Pharm Assoc (2003) 2004, 44:168-206. quiz 207-210.
23. Eliopoulos G.M. Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. J Infect 2009, 59(Suppl 1):S17-S24.